NCT01540812 - Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS | Biotech Hunter

Enrollment

418

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 20, 2019

Study Completion Date

December 1, 2019

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

Vincristine in induction

DRUG

Daunorubicin in induction

DRUG

Prednisone in induction

DRUG

Metotrexato in induction

DRUG

Cytarabine in induction

DRUG

Hydrocortisone in induction

DRUG

Idarubicin in induction-2

DRUG

Fludarabine in induction-2

DRUG

Ara-C in induction-2

DRUG

G-CSF in induction-2

DRUG

Dexamethasone in consolidation-1

DRUG

Vincristrine in consolidation-1

DRUG

Metotrexato in consolidation-1

DRUG

PEG-ASP in consolidation-1

DRUG

Dexamethasone in consolidation-2

DRUG

ARA-C in consolidation-2

DRUG

PEG-ASP in consolidation-2

DRUG

Dexamethasone in consolidation-3

DRUG

Vincristine in consolidation-3

DRUG

Metotrexato in consolidation-3

DRUG

PEG-ASP in consolidation-3

PROCEDURE

allogeneic HSCT

PROCEDURE

Allo HSCT with reduced-intensity conditioning

Trial Locations (1)

Unknown

Hospital Germans Trias i Pujol, Badalona

All Listed Sponsors

lead

PETHEMA Foundation

OTHER